Across all the models tested, the scientists report a 100% response rate. They deployed the treatment against pancreatic cancer specifically, but believe the results bode well for its wider application.
The landmark Phase 3 trial to explore the psychedelic’s ability to treat depression will enroll close to 1,000 participants and Compass is looking to U.S. FDA approval by the end of 2025.
The treatment from UC Davis Health involves administering a stem cell patch to the fetus’ spine while still developing in the womb, and early results are promising one year on.
The Alzheimer’s Association called the robust study from American biotech company Biogen “the most encouraging results in clinical trials treating the underlying causes of Alzheimer’s to date.”
The Chinese Academy of Sciences says the Zhangjiakou plant will save around 42,000 tons of coal from being burned in power stations, and reduce annual carbon dioxide emissions by around 109,000 tons.
The Serum Institute of India (SII), the world’s biggest vaccine maker, has developed the country’s first cervical cancer shot that will hit the market within a few months.
A new treatment from Friedrich-Alexander University in Germany drove the disease into remission in all of its five patients, who have now been off lupus medication for between three and 17 months.
Even low-level exposure to these chemicals over a sustained amount of time can lead to serious health effects, including thyroid disease, reduced immune response, and several cancers.
The double-blind longitudinal study followed nearly 1,000 patients with Lynch Syndrome, an inherited genetic condition that increases the individual risk of several cancers, for almost 20 years.
The Bochum researchers hope that an early diagnosis based on the amyloid-beta misfolding could help to apply Alzheimer’s drugs at such an early stage that they have a significantly better effect.
